DoW Breast Cancer, Breakthrough Award Level 3
The FY26 DoW Breast Cancer Breakthrough Award Level 3 funds high-impact research projects addressing key challenges in breast cancer, requiring consumer advocate involvement and allowing optional small clinical trials.
Funder: Dept. of the Army -- USAMRAA
Due Dates: June 12, 2026: Pre-Application (Preproposal) submission deadline (5:00 p.m. ET) | September 30, 2026: Full Application submission deadline (11:59 p.m. ET) | October 5, 2026: End of Application Verification Period deadline (5:00 p.m. ET)
Funding Amounts: Estimated total funding: $12.6M; up to $5.6M (single PI) or $7.0M (Partnering PI Option) per award over up to 4 years; 2 awards expected.
Summary: Supports advanced translational research projects with high potential to achieve breakthroughs in breast cancer, addressing key program challenges.
Key Information: Requires two or more breast cancer consumer advocates on the research team; open to domestic and foreign organizations.
Description
This opportunity, funded by the Department of the Army (USAMRAA) through the Congressionally Directed Medical Research Programs (CDMRP), supports advanced translational research projects with the potential to make significant breakthroughs in breast cancer. The Breakthrough Award Level 3 mechanism is designed for research that addresses at least one of the Breast Cancer Research Program (BCRP) overarching challenges and aims to accelerate progress toward ending breast cancer. Projects may include, but are not limited to, advanced translational studies and small-scale clinical trials (e.g., first-in-human, phase 1/1b). The award strongly emphasizes impact, innovation, and the integration of consumer advocate perspectives in the research process.
